Array BioPharma, Genentech expand oncology collaboration

By Jennifer Chiou

New York, Oct. 13 - Array BioPharma announced the second extension and expansion of its collaboration with Genentech, Inc. for the discovery of cancer drugs.

Under the expanded agreement, Genentech may provide about $50 million in research funding for Array's drug discovery platform over the next three years.

Array will be entitled to receive milestone payments based on the progress of clinical drug candidates and royalties on net sales of any products resulting from the collaboration. Specific terms were not disclosed.

"We believe our collaboration with Genentech further validates Array's leadership position in cancer research," chief executive officer Robert E. Conway said in a news release.

"This collaboration leverages Array's proprietary small molecule drug discovery expertise with Genentech's cancer expertise, with the goal of creating products to address one of the world's largest unmet medical needs and market opportunities."

Genentech will be responsible for the clinical development and marketing of products.

In January 2004, the companies entered into a collaboration to advance two of Array's proprietary oncology programs into clinical development. In April, the agreement was expanded to include an additional protein target in oncology.

Based in Boulder, Colo., Array BioPharma is a biopharmaceutical company focused on cancer and inflammatory disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.